Effect of drug for fetal lung maturation during pregnancy on mothers blood glucose levels and fetal well being

Effect of antenatal Dexamethasone therapy on maternal blood glucose levels and fetal well being - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069376

Enrollment

140

Registered

2024-06-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O429- Premature rupture of membranes, unspecified as to length of time between rupture and onset of labor

Interventions

Intervention1: Dexamethasone therapy: Dexamethasone therapy given as 6 mg 4 doses intramuscularly 12 hours apart for fetal lung maturation. Total duration of Dexamethasone therapy is 48 hours. There

Eligibility

Inclusion criteria

Inclusion criteria: 1 Pregnant women between 26-34 weeks of gestation with threatened preterm labor pains and premature rupture of membranes 2 Antenatal women between 34-39 weeks planned for lower segment cesarean section (LSCS)

Exclusion criteria

Exclusion criteria: 1) Pregnant women with pre-existing diabetes and gestational diabetes mellitus. 2) Pregnant women with fetal growth restriction. 3) Patients who require immediate termination of pregnancy or are in established preterm labor. 4) Pregnant women with evidence of infection, where corticosteroid therapy may lead to flare-up of infection. 5) Patients with chronic kidney disease, and pre-existing adrenal and pancreatic dysfunction. 6) Pregnant women who have received tocolysis with beta-mimetic agents. 7) Multifetal gestation.

Design outcomes

Primary

Measure	Time frame
1) To study the effect of Dexamethasone therapy on maternal blood glucose levels in pregnant women without diabetes mellitus 2) To study the fetal effects of antenatal Dexamethasone therapy including fetal movements, Biophysical profile, and Umbilical artery Doppler 3)To assess the neonatal outcome of antenatal dexamethasone therapy Timepoint: 1) blood glucose level in antenatal women will be determined at baseline followed by 3 days of premeal and post meal blood sugar levels. 2) fetal movements, biophysical profile, and umbilical artery Doppler will be done at baseline followed by 3 days of monitoring to study the effect of dexamethasone therapy on fetal well being.	—

Measure

Time frame

1) To study the effect of Dexamethasone therapy on maternal blood glucose levels in pregnant women without diabetes mellitus 2) To study the fetal effects of antenatal Dexamethasone therapy including fetal movements, Biophysical profile, and Umbilical artery Doppler 3)To assess the neonatal outcome of antenatal dexamethasone therapy Timepoint: 1) blood glucose level in antenatal women will be determined at baseline followed by 3 days of premeal and post meal blood sugar levels. 2) fetal movements, biophysical profile, and umbilical artery Doppler will be done at baseline followed by 3 days of monitoring to study the effect of dexamethasone therapy on fetal well being.

—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr Navneet Takkar

Government medical college and hospital ,sector 32 chandigarh

navneettakkar2015@gmail.com9646121582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026